Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

High FcγR Expression on Intratumoral Macrophages Enhances Tumor-Targeting Antibody Therapy.

Benonisson H, Sow HS, Breukel C, Claassens J, Brouwers C, Linssen MM, Fransen MF, Sluijter M, Ossendorp F, van Hall T, Verbeek JS.

J Immunol. 2018 Nov 5. pii: ji1800700. doi: 10.4049/jimmunol.1800700. [Epub ahead of print]

PMID:
30397036
2.

FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model.

Sow HS, Benonisson H, Breukel C, Visser R, Verhagen OJHM, Bentlage AEH, Brouwers C, Claassens JWC, Linssen MM, Camps M, van Hall T, Ossendorp F, Fransen MF, Vidarsson G, Verbeek JS.

Int J Cancer. 2018 Sep 27. doi: 10.1002/ijc.31899. [Epub ahead of print]

PMID:
30259976
3.

Cationic Liposomes: A Flexible Vaccine Delivery System for Physicochemically Diverse Antigenic Peptides.

Heuts J, Varypataki EM, van der Maaden K, Romeijn S, Drijfhout JW, van Scheltinga AT, Ossendorp F, Jiskoot W.

Pharm Res. 2018 Sep 12;35(11):207. doi: 10.1007/s11095-018-2490-6.

4.

FcγRI expression on macrophages is required for antibody-mediated tumor protection by cytomegalovirus-based vaccines.

Benonisson H, Sow HS, Breukel C, Claassens JWC, Brouwers C, Linssen MM, Redeker A, Fransen MF, van Hall T, Ossendorp F, Arens R, Verbeek S.

Oncotarget. 2018 Jun 29;9(50):29392-29402. doi: 10.18632/oncotarget.25630. eCollection 2018 Jun 29.

5.

Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences.

Chung CK, Da Silva CG, Kralisch D, Chan A, Ossendorp F, Cruz LJ.

J Control Release. 2018 Sep 10;285:56-66. doi: 10.1016/j.jconrel.2018.07.011. Epub 2018 Jul 6. Review.

PMID:
30008371
6.

Approaches to Improve Chemically Defined Synthetic Peptide Vaccines.

Hos BJ, Tondini E, van Kasteren SI, Ossendorp F.

Front Immunol. 2018 Apr 26;9:884. doi: 10.3389/fimmu.2018.00884. eCollection 2018. Review.

7.

Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System.

Fletcher EAK, van Maren W, Cordfunke R, Dinkelaar J, Codee JDC, van der Marel G, Melief CJM, Ossendorp F, Drijfhout JW, Mangsbo SM.

J Immunol. 2018 Jul 1;201(1):87-97. doi: 10.4049/jimmunol.1700911. Epub 2018 May 11.

PMID:
29752315
8.

Chemical Control over T-Cell Activation in Vivo Using Deprotection of trans-Cyclooctene-Modified Epitopes.

van der Gracht AMF, de Geus MAR, Camps MGM, Ruckwardt TJ, Sarris AJC, Bremmers J, Maurits E, Pawlak JB, Posthoorn MM, Bonger KM, Filippov DV, Overkleeft HS, Robillard MS, Ossendorp F, van Kasteren SI.

ACS Chem Biol. 2018 Jun 15;13(6):1569-1576. doi: 10.1021/acschembio.8b00155. Epub 2018 May 11.

9.

Sustained cross-presentation capacity of murine splenic dendritic cell subsets in vivo.

Ho NI, Camps MGM, de Haas EFE, Ossendorp F.

Eur J Immunol. 2018 Jul;48(7):1164-1173. doi: 10.1002/eji.201747372. Epub 2018 May 17.

10.

A Restricted Role for FcγR in the Regulation of Adaptive Immunity.

Fransen MF, Benonisson H, van Maren WW, Sow HS, Breukel C, Linssen MM, Claassens JWC, Brouwers C, van der Kaa J, Camps M, Kleinovink JW, Vonk KK, van Heiningen S, Klar N, van Beek L, van Harmelen V, Daxinger L, Nandakumar KS, Holmdahl R, Coward C, Lin Q, Hirose S, Salvatori D, van Hall T, van Kooten C, Mastroeni P, Ossendorp F, Verbeek JS.

J Immunol. 2018 Apr 15;200(8):2615-2626. doi: 10.4049/jimmunol.1700429. Epub 2018 Mar 9.

11.

Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses.

Mangsbo SM, Fletcher EAK, van Maren WWC, Redeker A, Cordfunke RA, Dillmann I, Dinkelaar J, Ouchaou K, Codee JDC, van der Marel GA, Hoogerhout P, Melief CJM, Ossendorp F, Drijfhout JW.

Mol Immunol. 2018 Jan;93:115-124. doi: 10.1016/j.molimm.2017.11.004. Epub 2017 Nov 22.

PMID:
29175591
12.

Hollow microneedle-mediated micro-injections of a liposomal HPV E743-63 synthetic long peptide vaccine for efficient induction of cytotoxic and T-helper responses.

van der Maaden K, Heuts J, Camps M, Pontier M, Terwisscha van Scheltinga A, Jiskoot W, Ossendorp F, Bouwstra J.

J Control Release. 2018 Jan 10;269:347-354. doi: 10.1016/j.jconrel.2017.11.035. Epub 2017 Nov 22.

13.

The potential of multi-compound nanoparticles to bypass drug resistance in cancer.

Da Silva CG, Peters GJ, Ossendorp F, Cruz LJ.

Cancer Chemother Pharmacol. 2017 Nov;80(5):881-894. doi: 10.1007/s00280-017-3427-1. Epub 2017 Sep 8. Review.

14.

Photodynamic-Immune Checkpoint Therapy Eradicates Local and Distant Tumors by CD8+ T Cells.

Kleinovink JW, Fransen MF, Löwik CW, Ossendorp F.

Cancer Immunol Res. 2017 Oct;5(10):832-838. doi: 10.1158/2326-6066.CIR-17-0055. Epub 2017 Aug 29.

15.

PD-L1 immune suppression in cancer: Tumor cells or host cells?

Kleinovink JW, van Hall T, Ossendorp F, Fransen MF.

Oncoimmunology. 2017 May 12;6(7):e1325982. doi: 10.1080/2162402X.2017.1325982. eCollection 2017.

16.

CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy.

Doorduijn EM, Sluijter M, Salvatori DC, Silvestri S, Maas S, Arens R, Ossendorp F, van der Burg SH, van Hall T.

Cancer Immunol Res. 2017 Aug;5(8):642-653. doi: 10.1158/2326-6066.CIR-16-0334. Epub 2017 Jun 21.

17.

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy.

Kleinovink JW, Marijt KA, Schoonderwoerd MJA, van Hall T, Ossendorp F, Fransen MF.

Oncoimmunology. 2017 Feb 21;6(4):e1294299. doi: 10.1080/2162402X.2017.1294299. eCollection 2017.

18.

C1q-Dependent Dendritic Cell Cross-Presentation of In Vivo-Formed Antigen-Antibody Complexes.

Ho NI, Camps MGM, de Haas EFE, Trouw LA, Verbeek JS, Ossendorp F.

J Immunol. 2017 Jun 1;198(11):4235-4243. doi: 10.4049/jimmunol.1602169. Epub 2017 Apr 21.

19.

Efficient Eradication of Established Tumors in Mice with Cationic Liposome-Based Synthetic Long-Peptide Vaccines.

Varypataki EM, Benne N, Bouwstra J, Jiskoot W, Ossendorp F.

Cancer Immunol Res. 2017 Mar;5(3):222-233. doi: 10.1158/2326-6066.CIR-16-0283. Epub 2017 Jan 31.

20.

Self-Assembling Peptide Epitopes as Novel Platform for Anticancer Vaccination.

Rad-Malekshahi M, Fransen MF, Krawczyk M, Mansourian M, Bourajjaj M, Chen J, Ossendorp F, Hennink WE, Mastrobattista E, Amidi M.

Mol Pharm. 2017 May 1;14(5):1482-1493. doi: 10.1021/acs.molpharmaceut.6b01003. Epub 2017 Jan 27.

21.

Strong in vivo antitumor responses induced by an antigen immobilized in nanogels via reducible bonds.

Li D, Sun F, Bourajjaj M, Chen Y, Pieters EH, Chen J, van den Dikkenberg JB, Lou B, Camps MG, Ossendorp F, Hennink WE, Vermonden T, van Nostrum CF.

Nanoscale. 2016 Dec 1;8(47):19592-19604.

PMID:
27748778
22.

The Optimization of Bioorthogonal Epitope Ligation within MHC-I Complexes.

Pawlak JB, Hos BJ, van de Graaff MJ, Megantari OA, Meeuwenoord N, Overkleeft HS, Filippov DV, Ossendorp F, van Kasteren SI.

ACS Chem Biol. 2016 Nov 18;11(11):3172-3178. Epub 2016 Oct 10.

PMID:
27704768
23.

TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients.

Zom GG, Welters MJ, Loof NM, Goedemans R, Lougheed S, Valentijn RR, Zandvliet ML, Meeuwenoord NJ, Melief CJ, de Gruijl TD, Van der Marel GA, Filippov DV, Ossendorp F, Van der Burg SH.

Oncotarget. 2016 Oct 11;7(41):67087-67100. doi: 10.18632/oncotarget.11512.

24.

Synthesis and evaluation of fluorescent Pam3Cys peptide conjugates.

Gential GP, Ho NI, Chiodo F, Meeuwenoord N, Ossendorp F, Overkleeft HS, van der Marel GA, Filippov DV.

Bioorg Med Chem Lett. 2016 Aug 1;26(15):3641-5. doi: 10.1016/j.bmcl.2016.05.094. Epub 2016 Jun 1.

PMID:
27289322
25.

Glycan modification of antigen alters its intracellular routing in dendritic cells, promoting priming of T cells.

Streng-Ouwehand I, Ho NI, Litjens M, Kalay H, Boks MA, Cornelissen LA, Kaur Singh S, Saeland E, Garcia-Vallejo JJ, Ossendorp FA, Unger WW, van Kooyk Y.

Elife. 2016 Mar 21;5. pii: e11765. doi: 10.7554/eLife.11765.

26.

Vaccines for established cancer: overcoming the challenges posed by immune evasion.

van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ.

Nat Rev Cancer. 2016 Apr;16(4):219-33. doi: 10.1038/nrc.2016.16. Epub 2016 Mar 11. Review.

PMID:
26965076
27.

Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticles.

Varypataki EM, Silva AL, Barnier-Quer C, Collin N, Ossendorp F, Jiskoot W.

J Control Release. 2016 Mar 28;226:98-106. doi: 10.1016/j.jconrel.2016.02.018. Epub 2016 Feb 11.

PMID:
26876760
28.

Combinatorial prospects of nano-targeted chemoimmunotherapy.

Da Silva CG, Rueda F, Löwik CW, Ossendorp F, Cruz LJ.

Biomaterials. 2016 Mar;83:308-20. doi: 10.1016/j.biomaterials.2016.01.006. Epub 2016 Jan 9. Review.

PMID:
26796043
29.

TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.

Doorduijn EM, Sluijter M, Querido BJ, Oliveira CC, Achour A, Ossendorp F, van der Burg SH, van Hall T.

J Clin Invest. 2016 Feb;126(2):784-94. doi: 10.1172/JCI83671. Epub 2016 Jan 19.

30.

PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity.

Silva AL, Soema PC, Slütter B, Ossendorp F, Jiskoot W.

Hum Vaccin Immunother. 2016 Apr 2;12(4):1056-69. doi: 10.1080/21645515.2015.1117714. Epub 2016 Jan 11. Review.

31.

Combination of Photodynamic Therapy and Specific Immunotherapy Efficiently Eradicates Established Tumors.

Kleinovink JW, van Driel PB, Snoeks TJ, Prokopi N, Fransen MF, Cruz LJ, Mezzanotte L, Chan A, Löwik CW, Ossendorp F.

Clin Cancer Res. 2016 Mar 15;22(6):1459-68. doi: 10.1158/1078-0432.CCR-15-0515. Epub 2015 Nov 6.

32.

Particulate Systems Based on Poly(Lactic-co-Glycolic)Acid (pLGA) for Immunotherapy of Cancer.

Rahimian S, Fransen MF, Kleinovink JW, Amidi M, Ossendorp F, Hennink WE.

Curr Pharm Des. 2015;21(29):4201-16. Review.

PMID:
26323429
33.

The viral context instructs the redundancy of costimulatory pathways in driving CD8(+) T cell expansion.

Welten SP, Redeker A, Franken KL, Oduro JD, Ossendorp F, Čičin-Šain L, Melief CJ, Aichele P, Arens R.

Elife. 2015 Aug 11;4. doi: 10.7554/eLife.07486.

34.

Therapeutic cancer vaccines.

Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH.

J Clin Invest. 2015 Sep;125(9):3401-12. doi: 10.1172/JCI80009. Epub 2015 Jul 27. Review.

35.

Lipophilic Muramyl Dipeptide-Antigen Conjugates as Immunostimulating Agents.

Willems MM, Zom GG, Meeuwenoord N, Khan S, Ossendorp F, Overkleeft HS, van der Marel GA, Filippov DV, Codée JD.

ChemMedChem. 2016 Jan 19;11(2):190-8. doi: 10.1002/cmdc.201500196. Epub 2015 Jun 9.

PMID:
26059481
36.

Synthetic Long Peptide Influenza Vaccine Containing Conserved T and B Cell Epitopes Reduces Viral Load in Lungs of Mice and Ferrets.

Rosendahl Huber SK, Camps MG, Jacobi RH, Mouthaan J, van Dijken H, van Beek J, Ossendorp F, de Jonge J.

PLoS One. 2015 Jun 5;10(6):e0127969. doi: 10.1371/journal.pone.0127969. eCollection 2015.

37.

Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer.

Rahimian S, Fransen MF, Kleinovink JW, Amidi M, Ossendorp F, Hennink WE.

Biomaterials. 2015 Aug;61:33-40. doi: 10.1016/j.biomaterials.2015.04.043. Epub 2015 May 17.

PMID:
25993015
38.

The translocon protein Sec61 mediates antigen transport from endosomes in the cytosol for cross-presentation to CD8(+) T cells.

Zehner M, Marschall AL, Bos E, Schloetel JG, Kreer C, Fehrenschild D, Limmer A, Ossendorp F, Lang T, Koster AJ, Dübel S, Burgdorf S.

Immunity. 2015 May 19;42(5):850-63. doi: 10.1016/j.immuni.2015.04.008. Epub 2015 May 12.

39.

Bioorthogonal deprotection on the dendritic cell surface for chemical control of antigen cross-presentation.

Pawlak JB, Gential GP, Ruckwardt TJ, Bremmers JS, Meeuwenoord NJ, Ossendorp FA, Overkleeft HS, Filippov DV, van Kasteren SI.

Angew Chem Int Ed Engl. 2015 May 4;54(19):5628-31. doi: 10.1002/anie.201500301. Epub 2015 Mar 17.

PMID:
25784151
40.

Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.

Rahimian S, Fransen MF, Kleinovink JW, Christensen JR, Amidi M, Hennink WE, Ossendorp F.

J Control Release. 2015 Apr 10;203:16-22. doi: 10.1016/j.jconrel.2015.02.006. Epub 2015 Feb 7.

PMID:
25660830
41.

Two in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule.

Zom GG, Filippov DV, van der Marel GA, Overkleeft HS, Melief CJ, Ossendorp F.

Oncoimmunology. 2014 Jul 3;3(7):e947892. eCollection 2014.

42.

Poly-(lactic-co-glycolic-acid)-based particulate vaccines: particle uptake by dendritic cells is a key parameter for immune activation.

Silva AL, Rosalia RA, Varypataki E, Sibuea S, Ossendorp F, Jiskoot W.

Vaccine. 2015 Feb 11;33(7):847-54. doi: 10.1016/j.vaccine.2014.12.059. Epub 2015 Jan 7.

PMID:
25576216
43.

Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death.

van der Sluis TC, van Duikeren S, Huppelschoten S, Jordanova ES, Beyranvand Nejad E, Sloots A, Boon L, Smit VT, Welters MJ, Ossendorp F, van de Water B, Arens R, van der Burg SH, Melief CJ.

Clin Cancer Res. 2015 Feb 15;21(4):781-94. doi: 10.1158/1078-0432.CCR-14-2142. Epub 2014 Dec 12.

44.

CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.

Rosalia RA, Cruz LJ, van Duikeren S, Tromp AT, Silva AL, Jiskoot W, de Gruijl T, Löwik C, Oostendorp J, van der Burg SH, Ossendorp F.

Biomaterials. 2015 Feb;40:88-97. doi: 10.1016/j.biomaterials.2014.10.053. Epub 2014 Nov 26.

PMID:
25465442
45.

Near-infrared labeled, ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine: In vivo tracking and evaluation of antigen-specific CD8(+) T cell immune response.

Rahimian S, Kleinovink JW, Fransen MF, Mezzanotte L, Gold H, Wisse P, Overkleeft H, Amidi M, Jiskoot W, Löwik CW, Ossendorp F, Hennink WE.

Biomaterials. 2015 Jan;37:469-77. doi: 10.1016/j.biomaterials.2014.10.043. Epub 2014 Oct 28.

PMID:
25453974
46.

Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity.

Varypataki EM, van der Maaden K, Bouwstra J, Ossendorp F, Jiskoot W.

AAPS J. 2015 Jan;17(1):216-26. doi: 10.1208/s12248-014-9686-4. Epub 2014 Nov 12.

47.

FcRγ-chain ITAM signaling is critically required for cross-presentation of soluble antibody-antigen complexes by dendritic cells.

Boross P, van Montfoort N, Stapels DA, van der Poel CE, Bertens C, Meeldijk J, Jansen JH, Verbeek JS, Ossendorp F, Wubbolts R, Leusen JH.

J Immunol. 2014 Dec 1;193(11):5506-14. doi: 10.4049/jimmunol.1302012. Epub 2014 Oct 29.

48.

Enhanced cross-presentation and improved CD8+ T cell responses after mannosylation of synthetic long peptides in mice.

Rauen J, Kreer C, Paillard A, van Duikeren S, Benckhuijsen WE, Camps MG, Valentijn AR, Ossendorp F, Drijfhout JW, Arens R, Burgdorf S.

PLoS One. 2014 Aug 19;9(8):e103755. doi: 10.1371/journal.pone.0103755. eCollection 2014.

49.

Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study.

Cruz LJ, Rosalia RA, Kleinovink JW, Rueda F, Löwik CW, Ossendorp F.

J Control Release. 2014 Oct 28;192:209-18. doi: 10.1016/j.jconrel.2014.07.040. Epub 2014 Jul 25.

PMID:
25068703
50.

N-tetradecylcarbamyl lipopeptides as novel agonists for Toll-like receptor 2.

Willems MM, Zom GG, Khan S, Meeuwenoord N, Melief CJ, van der Stelt M, Overkleeft HS, Codée JD, van der Marel GA, Ossendorp F, Filippov DV.

J Med Chem. 2014 Aug 14;57(15):6873-8. doi: 10.1021/jm500722p. Epub 2014 Jul 23.

PMID:
25019313

Supplemental Content

Loading ...
Support Center